Key result
Early percutaneous coronary intervention (day 1) with eptifibatide was associated with the lowest 30-day rate of death and myocardial infarction (9.2%, P<0.05 vs other groups).
Why the study?
Does early percutaneous coronary intervention combined with eptifibatide reduce 30-day death and myocardial infarction in patients with non-ST elevation acute coronary syndromes?
Population
2,430 patients with acute coronary syndromes without persistent ST elevation who underwent percutaneous…
Comparison
Eptifibatide for 72 hours combined with early… vs Placebo with percutaneous coronary intervention…
Design
Cohort
Follow-up
30 days
Authors
Loading...
May support early PCI with eptifibatide in NSTE-ACS; hypothesis-generating and requires randomized confirmation.
Cohort (n=2,430)
Does early percutaneous coronary intervention combined with eptifibatide reduce 30-day death and myocardial infarction in patients with non-ST elevation acute coronary syndromes?
p-value: p=<0.05
An early invasive strategy (PCI within 24 hours) under the protection of eptifibatide is associated with the lowest 30-day rate of death and myocardial infarction in patients with NSTE-ACS.
Eelko Ronner (2002) conducted a cohort in Acute coronary syndromes without persistent ST elevation (n=2,430). Early percutaneous coronary intervention (day 1) with eptifibatide vs. Later percutaneous coronary intervention and/or placebo was evaluated on 30-day events (death and myocardial infarction) (p=<0.05). Early percutaneous coronary intervention (day 1) with eptifibatide was associated with the lowest 30-day rate of death and myocardial infarction (9.2%, P<0.05 vs other groups).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: